Bloomberg Intelligence: Slump in Bitcoin Continues (Podcast)

Gold has outperformed as a hedge, consolidating above $4,000 and up more than 50% year-to-date, while Bitcoin has weakened—tumbling over 30% since October and down roughly 7% YTD—highlighting a shift in risk positioning. Separately, a pill formulation of Novo Nordisk’s Ozempic failed to slow Alzheimer’s progression in two long-shot studies, dashing an avenue for expanded indications, and US broadcasters such as Nexstar and Sinclair see potential upside from FCC moves to ease a 39% ownership cap, though President Trump’s opposition adds political uncertainty to the deregulatory path.

Analysis

Market structure is shifting from speculative risk to realized safe‑haven demand; expect continued ETF and miner inflows (GLD, GDX) that boost spot/backwardation in physical gold while compressing crypto futures basis and lowering BTC funding rates over the next 1–3 months. Broadcasters (NXST, SBGI) stand to gain optionality from cap relief, but upside is binary and concentrated around the timing and wording of FCC rule changes and any executive pushback.

Tail risks include a sudden Fed pivot that lifts real yields and reverses gold flows, a political veto that derails FCC changes or prompts swift sell‑offs in regional media, and idiosyncratic biotech surprises (e.g., secondary analyses or competing drugs) that reprice NVO materially; these could materialize within days to quarters. Hidden dependencies: insurer/payer responses to new indications and broadcaster balance‑sheet leverage dynamics can amplify moves beyond headline drivers.

Actionable trade set-ups: favor asymmetric long exposure to gold via 3–6 month call spreads on GLD or small outright longs in GDX (target 1.5–3% portfolio risk) and hedge crypto tail risk with 1‑month ATM put buys or 3:1 put spreads on BTC futures (size 0.5–1%). Express view on media via 4–6 month NXST/SBGI call spreads sized 1% with a political‑risk stop; for NVO, express downside via 3–6 month put spreads (5–10% OTM) rather than outright short to limit single‑name gamma.

Consensus is underestimating persistence of gold flows if real yields drift down modestly (25–50bp) and overestimating the permanence of NVO downside—diabetes franchise cashflow caps valuation downside and could attract buybacks if market overreacts. Historical parallels (2016 risk‑off gold surge, 2018 biotech binary readjustments) suggest event‑driven reversals can be sharp; manage positions with explicit triggers (CPI, Fed minutes, FCC vote within 60–120 days).

Key Decisions for Investors

• Establish a 2–3% portfolio position in GLD via a 3‑6 month 1.5%/5% OTM call spread to capture continued safe‑haven inflows while capping premium paid; widen if real yields fall another 20–50bp.
• Add 1–2% long exposure to GDX (miners) for convexity to gold moves; size so max drawdown equals 0.5% portfolio and place a 15% trailing stop to preserve gains on rapid spikes.
• Buy 3‑month ATM BTC puts equal to 0.5–1% portfolio notional (or short BTC perpetuals sized similarly) to hedge elevated tail risk; cut hedge if BTC rallies >15% in 14 days or funding rates normalize.
• Initiate a tactical 1% position in NXST (or SBGI) via 4–6 month call spreads (buy 10–20% OTM, sell 30–40% OTM) ahead of FCC rule votes; if no favorable language within 90 days, close or roll down.
• Implement a defensive 1–2% NVO downside trade via 3–6 month put spreads (buy 5–10% OTM, sell 15–20% OTM) to monetize binary biotech risk while limiting capital at risk; widen exposure only if share price falls >12% after follow‑up analyses.